HLA-G in organ transplantation: towards clinical applications

Deschaseaux, Frédéric; Delgado, Diego; Pistoia, Vito; Giuliani, Massimo; Morandi, Fabio; Dürrbach, Antoine

doi:10.1007/s00018-010-0581-6

Cited by 53 publications

(38 citation statements)

References 101 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It was found that the HLA-G 14 bp insertion polymorphism in the 3´UTR is responsible for a decrease in the mRNA level of most membrane and soluble isoforms [15]. The possible impact of the HLA-G 14 bp variant on kidney graft be up-regulated by stressors such as hypoxia, cytokines like IFN-g, TNF, IL-10, TGF-b, immunosuppressive agents or progressive doses of progesterone [34,35]. In relation to HLA-G expression, the time-course of serum HLA-G in patients after kidney transplantation has been examined by only few studies to date [18,31].…”

Section: Discussionmentioning

confidence: 99%

“…The explanation of such HLA-G expression is mostly unknown and needs to be elucidated more precisely. It was observed that individual immunosuppressive agents can decrease HLA-G expression; however the sHLA-G levels are still higher in patients without rejection [35]. acceptance has been investigated by various authors, but the results are controversial.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Impact of HLA-G 14 bp polymorphism and soluble HLA-G level on kidney graft outcome

Ďurmanová

Bandžuchová²,

Žilinská

et al. 2016

Open Life Sciences

View full text Add to dashboard Cite

Human leukocyte antigen G (HLA-G) is a non-classical HLA class I protein with various immunosuppressive functions. Besides its profound effect to induce fetal tolerance, HLA-G has been also found to enhance graft acceptance. The aim of the study was to analyse the association between HLA-G 14 bp insertion/deletion polymorphism, soluble HLA-G level and kidney graft outcome in the Slovak population. We investigated 69 kidney transplant recipients aged 27–65 years. Out of this group, 37 recipients developed acute rejection, confirmed by biopsy, and 32 patients had stable allograft function. Plasma was obtained from recipients at 1 day before transplantation and analyzed by ELISA. Genotyping of HLA-G polymorphism was performed by PCR. Significantly higher pre-transplantation levels of sHLA-G were found in the group with stable allograft function in comparison to group with acute rejection (P = 0.0409). In the homozygous −14/−14 recipients with stable allograft function, significantly higher values of sHLA-G were determined in comparison to the recipients with acute rejection (P = 0.0052). The study revealed an association between 14 bp deletion polymorphism and soluble HLA-G level that is proportional to kidney graft acceptance. It is suggested that pre-transplantation levels of soluble HLA-G should be monitored as additional marker to predict kidney graft outcome.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Impact of HLA-G 14 bp polymorphism and soluble HLA-G level on kidney graft outcome

Ďurmanová

Bandžuchová²,

Žilinská

et al. 2016

Open Life Sciences

View full text Add to dashboard Cite

show abstract

“…In physiological conditions, HLA-G expression was also found in erythroid precursors, cornea, thymic medulla and pancreatic islets (8,(9)(10)(11). However, HLA-G can be neoexpressed in pathological conditions including cancers, transplantation, and inflammatory and autoimmune diseases and viral infections (3,5,12,13).…”

Section: Mechanisms Of Hla-g Involved In Tumor Immunologymentioning

confidence: 99%

Human Leukocyte Antigen-G (HLA-G) Expression in Cancers: Roles in Immune Evasion, Metastasis and Target for Therapy

Lin

Yan

2015

Mol Med

109

View full text Add to dashboard Cite

Aberrant induction of human leukocyte antigen-G (HLA-G) expression has been observed in various malignancies and is strongly associated with tumor immune escape, metastasis and poor prognosis. To date, great achievements have been made in understanding the underlying mechanisms of HLA-G involved in tumor progression. HLA-G could lead to tumor evasion by inhibition of immune cell cytolysis, differentiation and proliferation and inhibition of cytokine production, induction of immune cell apoptosis, generation of regulatory cells and expansion of myeloid-derived suppressive cells and by impairment of chemotaxis. Moreover, HLA-G could arm tumor cells with a higher invasive and metastatic potential with the upregulation of tumor-promoting factor expression such as matrix metalloproteinases (MMPs), indicating that ectopic HLA-G expression could render multiple effects during the progression of malignancies. In this review, we summarized the mechanisms of HLA-G involved in promoting tumor cell immune escaping, metastasis and disease progression. Special attention will be paid to its significance as an attractive therapeutic target in cancers.

show abstract

“…Many HLA-G functions were described in vitro, because its expression is critically dependent on microenvironmental parameters. Based on all these findings, it is clear that there is a pathologic significance of HLA-G expression in vivo in the contexts of cancer (26), transplantation (27), autoimmune diseases, inflammatory diseases, and viral infections (28). …”

Section: Modulation Of Regulatory/suppressor Cellsmentioning

confidence: 99%

Molecular Pathways: Human Leukocyte Antigen G (HLA-G)

Curigliano

Criscitiello

Gelao

et al. 2013

Clinical Cancer Research

109

108

View full text Add to dashboard Cite

Human leukocyte antigen G (HLA-G) is a nonclassical MHC class I molecule that exerts important tolerogenic functions. Its main physiologic expression occurs in the placenta, where it participates in the maternal tolerance toward the fetus. HLA-G expression was found in embryonic tissues, in adult immune privileged organs, and in cells of the hematopoietic lineage. It is expressed in various types of primary solid (melanoma, head and neck, lung, urogenital, gastrointestinal, and breast cancers) and hematologic malignancies (acute leukemia, lymphomas) and metastases. HLA-G ectopic expression is observed in cancer, suggesting that its expression is one strategy used by tumor cells to escape immune surveillance. In this review, we will focus on HLA-G expression in cancers and its association with the prognosis. We will highlight the underlying molecular mechanisms of impaired HLA-G expression, the immune tolerant function of HLA-G in tumors, and the potential diagnostic use of membrane-bound and soluble HLA-G as a biomarker to identify tumors and to monitor disease stage. As HLA-G is a potent immunoinhibitory molecule, its blockade remains an attractive therapeutic strategy against cancer.

show abstract

HLA-G in organ transplantation: towards clinical applications

Cited by 53 publications

References 101 publications

Impact of HLA-G 14 bp polymorphism and soluble HLA-G level on kidney graft outcome

Impact of HLA-G 14 bp polymorphism and soluble HLA-G level on kidney graft outcome

Human Leukocyte Antigen-G (HLA-G) Expression in Cancers: Roles in Immune Evasion, Metastasis and Target for Therapy

Molecular Pathways: Human Leukocyte Antigen G (HLA-G)

Contact Info

Product

Resources

About